Related Experiment Videos
Sotalol: a novel beta-blocker with class III anti-arrhythmic activity
1Department of Medicine, Mount Sinai Medical Center, New York, New York.
Journal of Clinical Pharmacology
|June 1, 1993
Summary
Sotalol, a beta-blocker, also acts as a Class III anti-arrhythmic. Its dual action on repolarization and refractory periods makes it effective for treating various heart rhythm disorders.
Area of Science:
- Pharmacology
- Cardiology
- Electrophysiology
Background:
- Sotalol, synthesized in 1960, is a unique medication.
- It exhibits both beta-adrenoreceptor blocking and Class III anti-arrhythmic properties.
Purpose of the Study:
- To highlight the dual pharmacological actions of sotalol.
- To underscore its therapeutic potential in managing cardiac arrhythmias.
Main Methods:
- Review of sotalol's known mechanisms of action.
- Analysis of its effects on cardiac electrophysiology.
Main Results:
- Sotalol lengthens cardiac repolarization.
- It prolongs effective refractory periods in all cardiac tissues.
- These effects are in addition to its beta-blocking capabilities.
Conclusions:
- Sotalol's combined beta-blocking and anti-arrhythmic effects are beneficial.
- It is a valuable therapeutic option for supraventricular and ventricular arrhythmias.